Hepatic Function Panel

What the laboratory says this test is for

About 10-30% of patients continue with lingering symptoms four or more weeks after COVID-19 infection, including those who had mild, or no symptoms termed as post-COVID conditions. The Centers for Disease Control (CDC) provided Interim Guidance for Assessment and Testing for Evaluating and Caring for Patients with Post-COVID Conditions. The CDC recommends laboratory testing be guided by the patient history, physical examination, and clinical findings. A basic panel of laboratory tests might be considered for patients with ongoing symptoms to assess for conditions that may respond to treatment, until more information and evidence is available for specific laboratory testing for post-COVID conditions. This panel is to be considered for basic testing if no previous testing was performed.

What the laboratory says this test is for

This panel is useful in assessing the risk of any underlying medical conditions prior, during, and after initiation of therapy for Hepatitis C. This baseline profile does not include Hepatitis A or Hepatitis B testing, under the assumption this testing has already been performed. If these tests are desired, consider using 91704 (Hepatitis C-Infected Patient, Baseline Panel 1) or ordering separately. The relevant laboratory monitoring has been defined in the most recent AASLD guidelines.

What the laboratory says this test is for

This panel is important to baseline the laboratory parameters in order to define change on therapy as well as to assess the risk of any underlying medical conditions prior to initiation of therapy for Hepatitis C.